Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting

PR Newswire May 15, 2013

Halozyme Reports First Quarter 2013 Financial Results

PR Newswire May 8, 2013

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference

PR Newswire May 7, 2013

Halozyme to Host First Quarter 2013 Financial Results Conference Call

PR Newswire May 1, 2013

Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer

PR Newswire April 23, 2013

Free Research Reports on BA, HALO, LSCC and RNF Issued by the Paragon Report

Marketwired April 22, 2013

Free Research Reports on CLSN, CREE, HALO and TSO Issued by the Bedford Report

Marketwired April 8, 2013

Halozyme Therapeutics Names Matt Posard to Board of Directors

PR Newswire March 28, 2013

InvestorsGuru.com Filtered Mid-Day Market Movers Recap

Investors Guru March 24, 2013

Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union

PR Newswire March 22, 2013

New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012

Marketwired March 11, 2013

Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference

PR Newswire March 5, 2013

Halozyme Reports Fourth Quarter and Year End 2012 Financial Results

PR Newswire February 25, 2013

Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call

PR Newswire February 19, 2013

FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High

Marketwired February 7, 2013

Free Research Reports on HALO, LULU, RFMD and TWO Issued by the Bedford Report

Marketwired January 15, 2013

Free Research Reports on BCRX, HALO, HOLX and TELK Issued by the Bedford Report

Marketwired January 14, 2013

Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013

Marketwired January 14, 2013

The Real Story Behind HALO, SPPI, DVAX and LLY

Marketwired January 10, 2013

Halozyme Therapeutics Issues Financial Guidance For 2013

PR Newswire January 7, 2013